Method of producing derivatives of substituted benzamide or their pharmaceutically acceptable acid-a

专利摘要:
The subject matter of the invention are compounds of the formula: <CHEM> wherein R, R1, R2, R3, R4, R5, X and m and n are defined as in the patent claims, and acid additional salts, quaternary ammonium salts and N-oxide derivatives thereof, processes for preparation thereof, and pharmaceutical compositions containing the same. Said compounds, salts and N-oxide derivatives thereof show excellent gastro-intestinal motility enhancing activity.
公开号:SU1597101A3
申请号:SU874202484
申请日:1987-04-29
公开日:1990-09-30
发明作者:Кон Тацуя；Като Сиро；Морие Тосия；Охно Казунори；Хино Кацухико；Карасава Тадахико；Есида Наоюки
申请人:Дайниппон Фармасьютикал Ко, Лтд (Фирма)；
IPC主号:

专利说明:

This invention relates to the field of organic chemistry, in particular, to a process for the preparation of new derivatives of substituted benzamide capable of stimulating the motility of the stomach and intestines. The aim of the invention is to create a method for obtaining new compounds of the substituted benzamide series, with increased ability to stimulate the motility of the stomach and intestines with reduced toxicity in this series of compounds. Identification of compounds by elemental analysis, mass spectrum analysis, IR spectrum, NMR spectrum etc. PRI me R 1. Preparation of 4-amino-5-chloro-2-ethoxy-K- {4- (4-fluorobenzyl) 2-morpholinyl J methyl benzamide, 1 ° K to a solution of 2-aminomethyl-4- (4-fluorobenzyl) morpholine (2.5 g a) 4-amino-5-chloro-2-ethoxybenzoic acid (2.7 g) and 1-ethyl-3- (3-dimethylaminopropyl) carbodiimo hydrochloride (2.4 g) are added to dichloromethane (50 ml), a mixture of stirred at for 4 h. The reaction mixture was successively washed with water, with aqueous sodium hydroxide solution and with a saturated aqueous solution of sodium chloride, dried over magnesium sulphate and evaporated under reduced pressure. The residue is recrystallized from ethyl alcohol I to give the title compound (3.0 g, m.p. 151-153 C. 2. The free base (2.0 g) obtained in part 1 of this example is dissolved in ethyl alcohol (50 ml and added 35% hydrochloric acid (5.0 ml) in ethanol are precipitated and collected and recrystallized from ethyl alcohol to obtain the hydrochloride (1.6 g) of the title compound, mp 160-163 ° C 3c Free base (7.0 g), obtained in part 1 of this example, is dissolved in hot ethyl alcohol (100 ml) and citric acid monohydrate (3.8 g) is added. until a clear solution is obtained, which is concentrated to 20 ml and cooled. The precipitate is collected and recrystallized from ethyl alcohol. A citrate (8.6 g) of the title compound is obtained, m.plc 143-1 4. Free base (1.0 g), obtained in part 1 of this example is dissolved in a hot 10% citric acid aqueous solution (40 ml) and the resulting solution is cooled. The precipitate is collected and the dihydrate (g) of the title compound is obtained, mp. 110-113 Co Example 2. Preparation of 4-amino-5-chloro-2-ethoxy-K-4- (4-fluorobenzyl) -2-morpholinyl methyl Ybenzamido To a stirred suspension of 4-amino-5-chloro-2-ethoxybenzoic acid ( 2.9 g) in dichloromethane (50 ml) at 25 ° C, triethylamine (1.6 g) is added. The resulting mixture is cooled before and isobutyl chloroformate ester (2.0 g) is slowly added. After the reaction mixture is stirred at the same temperature, a solution of 2-aminomethyl-4- (4-fluorobenzyl) morpholine (3.0 g ) in dicloromethane (10 ml). The reaction mixture is stirred for 1 h at (-10) (-5) C. and then at 25 is left under stirring overnight. The mixture is successively washed with water, 10% aqueous sodium hydroxide solution and saturated aqueous sodium chloride solution, dried over sulfate magnesium and evaporated under reduced pressure. The residue is recrystallized from ethyl alcohol to give the desired compound (.4.1 g) with m.p. 151-153 C „Example 3 Preparation of 4-amino-N- 3- (4-benzyl-2-morpholinyl) -propyl-5-chloro-2-methoxybenzamide. To a mixture of 2- (3-aminopropyl) -4-benzylmorpholine (2.0 g), 4-amino-5-chloro-2-methoxybenzoic acid (1.7 g) and dichloromethane (40 ml) was added 1-ethyl hydrochloride -3- (3-dimethylaminopropyl) -carbodiimide (1.8 g) and the mixture is stirred at 25 ° C for 4 hours. Rinse sequentially with water, 10% aqueous sodium hydroxide solution, and saturated aqueous sodium chloride solution, dried over sulfate magnesium and evaporated under reduced pressure. The residue is dissolved in chloroform and chromatographed on silica gel. The eluate with chloroform is discarded, and the subsequent eluates from a mixture of methyl alcohol and chlorofo1 1a (in a ratio of 1: 9) are collected and evaporated to give the desired compound (2.5 g) as an oil
The free base thus obtained was dissolved in ethyl alcohol (50 ml), and a solution of oxalic acid (0.6 g) in ethyl alcohol (10 ml) was added. The resulting solution was concentrated to 10 ml and diethyl ether was added until cloudy. The precipitate is collected, recrystallized from ethyl alcohol and receive the oxalate hemihydrate of the target compound, mp 118-121 Co
Example 4, Preparation 3, A-detotilenedioxy-L- (4-benzip-2-morpholinyl) methyl benzamide.
 A mixture of 3,4-methylenedioxybenzoic acid (2.0 g), thionyl chloride (1.7 g), dimethylformamide (one drop) and chloroform (25 ml) is heated under reflux with stirring for 1 h. After removing chloroform at toluene (20 ml) was added under reduced pressure and the resulting solution was evaporated under reduced pressure. The residue was dissolved in chloroform (25 ml) and triethylamine (10 ml) was added. To the mixture is added dropwise a solution of 2-aminomethyl-4-benz-1-morpholine (2.5 g) in chloroform (25 ml). The reaction mixture was left overnight with stirring at 25 ° C and then washed successively with water, 1N. an aqueous solution of sodium hydroxide and a saturated aqueous solution of sodium chloride, and dried over magnesium sulfate. The solvent is distilled off under reduced pressure to obtain the target compound (4.0 g). The free base thus obtained is treated with fumaric acid in hot isopropyl alcohol. The precipitate is collected, recrystallized from isopropyl alcohol to give 3/4 fumarate of the title compound, about 161-163 ° C,
Example 5. Obtaining 4-amino-5-hlop-N- | 4-ethoxycarbonyl-2-morpholinyl) methyl -2-methoxybnnzamide.
To a solution of 2-aminomethyl-4-ethoxycarbonylmorpholine (5.8 g) in dichloromethane (100 ml) were added 4-amino-5-xpor-2-methoxybenzoic acid (5.0 g) and 1-ethyl-3 hydrochloride ( 3-dimethylaminopropyl) carbodiimide (5.2 g and the resulting mixture is stirred at 25 ° C for 4 hours. The reaction mixture is sequentially washed with water, an aqueous solution of hydroxide
sodium and saturated with an aqueous solution of sodium chloride and dried over magnesium sulphate. The solvent is distilled off under reduced pressure. The residue is dissolved in chloroform and chromatographed on silica gel. The eluate with chloroform is discarded, and the subsequent eluates from a mixture of methyl alcohol and chloroform (in a ratio of 1: 9) are combined, evaporated and the desired compound (7.5 g) is obtained as an oil.
The free base thus obtained is treated with oxalic acid according to Example 3 and an oxalate of the title compound is obtained with m, pl. 140151 C (recrystallization from a mixture of ethyl alcohol - diethyl ether).
Example 6, Preparation of 4-am5 on-5-chloro-N-4- (4-cyanobenzyl) -2-morpholinyl methyl} -2-methoxybenz-. mida
one . To a solution of 2-aminomethyl-4- (4-cyanobenzyl) morpholine (1.5 g) in dichloromethane (40 ml) was added 4.-amino-5-chloro-2-methoxybenzoic acid (1-, 2 g) and hydrochloride 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (1.3 g) and the resulting mixture is stirred at 25 ° C for 3 hours. The reaction mixture is successively washed with water, an aqueous solution of sodium hydroxide and a saturated solution of sodium chloride and dried over magnesium sulfate. The solvent is distilled off at
5 reduced pressure and get the target compound in the form of oil.
2. The free base is dissolved in a small amount of ethanol and the solution of fumaric acid is added.
0 acid (0.7 g) in ethyl alcohol (20 ml). The resulting solution is concentrated to 10 ml and cooled. The precipitate is collected, recrystallized from ethyl alcohol and get fumarat
5 target compound. With t about pl. 163167С.
Example 7: Preparation of 4-acetylamino-5-chloro-2-ethoxy-K-C4- (4-fluorobenzip) -2-morpholinyl methyl ben0 3 amide.

权利要求:
Claims (2)
[1]
To a stirred mixture of 4-acetylamino-5-chloro-2-ethoxybenzoic acid (2.0 g), .2-amino-compounds I-4- (4-fluorobenzyl) morpholine (1.6 g) and di-sourmethane- (20 ml), add 1-ethyl1 - (3-dimesh1aminopropyl) carbodiimide hydrochloride (1.5 g) and the mixture is stirred at 1.5 h. 7 The reaction mixture is successively washed with water, an aqueous solution of sodium hydroxide and an all-saturated aqueous solution of sodium chloride, dried over magnesium sulphate and evaporated. The residue is recrystallized from ethanol and gives the desired compound (2.1 g), t "pl. 161-163C. Example 8 Preparation of 4-amino-Y-2- (4-benzyl-2-morpholinyl) ethyl-5-chloro-2-ethoxybenzamide. The compound was prepared as in Example 1 using 2- (2-amino-ethyl) -4-benzylmorpholine instead of 2 -aminoethyl-4 (4-fluoro benzyl) -morpholine; mp, 149-1 51 ° C (recrystallization from methyl alcohol). Example 9: Preparation of 4-amino-K-1 .2- (4-benzyl-2-morpholinyl) ethyl-5-chloro-2-methoxybenzymes a. The compound is prepared, as in Example 6 (1), using 2- (2-aminoethyl) -4-benzylmorpholine instead of 2-aminomethyl-4- (4-cyanobasyl) morpholine. The resulting free base is treated as Example 6 B (2), and semi-fumarate 3 EtOH is obtained with a melting point of 68-72 b (from ethyl alcohol-diethyl ether mixture). Example 10o Preparation of 4 amino-M-. 2-14- (4-cyanobenzyl) -2-morpholi-5-chloro-2-methoxybenzamide 1/4 hydrate of the title compound as in Example 6 (1) is obtained, using 2- ( 2-aminoethyl) -4- (4-cyanobenzyl) morpholine instead of 2-aminomethyl-4- (4-iianobenzyl) morpholine. T. pl. (from isopropyl alcohol) a) Example 11. Preparation of 2,3-methylenedioxy-N- (4-benzyl-2-morpholinyl) -methylZbenzamide. The target compound is obtained, as in Example 6 (1), using 2-aminomethyl-4-benzylmorpholine and 2,3-methylenedioxybenzoic acid, respectively, instead of 2-aminomethyl-4- (4-cy anobenzyl) morpholine and 4-amino- 5-chloro-2-methoxybenzoic acid The free base thus obtained is treated as in Example 6 (2) and 1/4 fumarate hydrate of the title compound is obtained. That pls 144-146C (from ethyl alcohol). Example 12, Preparation of 5. Por-E-H14- (3- (4-chlorophenoxy) propyl 1 8 -2-morpholinyl methyl-4-dimethylamino-2-methoxybenzamide. The hemihydrate of the title compound is obtained as in Example 6 ( 1) using 2-aminomethyl-4-G3- (4-chlorophenoxy) propyl morpholine and 5-chloro-4-dimethylamino-2-methoxybenzoic acid, respectively, instead of 2-aminomethyl-4- (4-cyanobenzyl) morpholine and 4-amino -5-chloro-2-methoxybenzoic acid, T. m.p. 128-13O C (from ethyl alcohol) o Example 13, Preparation of 5-chloro-N-4- (4-cyanobenzyl) -2-moprofolinyl -methyl 5-4-dimethylamino-2 sibenzamide labels Example 6 (1), using 5-chloro-4-dimethylamino-2-methoxybenzoic acid instead of 4-amino-5-chloro-2-meg toxybenzoic acid. T, pl 161163 ° C (from ethanol). Example 14 Preparation 4-amino-5-chloro-N-iL4- (2-chlorophenyl) -6-methyl-2-morpholinyl methyl J-2-ethoxybenzamide, 1 o K solution of 2-aminomethyl-4- (2-chlorobenzyl) - 6-methylmorpholine (2.2 g) in dichloromethane (50 ml) were added 4-amino-5-chloro-2-ethoxybenzoic acid (1.9 g) and 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride ( 1.7 g) The reaction mixture is stirred at 25 ° C for 4 hours, rinsed successively with water, an aqueous solution of sodium hydroxide and a saturated aqueous solution of sodium chloride and dried over magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was chromatographed over silica gel with ethyl acetate-hexane chloroform (). The desired compound (2.6 g) is obtained in the form of an oil. 2. The free base (2.6 g) is dissolved in ethanol (50 ml) and a solution of fumaric acid (1.5 g) in ethanol (20 ml) is added. The resulting solution is concentrated to 10 ml. The precipitate is collected and recrystallized from isopropyl alcohol. The difumarate of the title compound is obtained, mp. 150-154 sec. PRI and m-p 15. Obtaining 4-amipo-5-chloro-N- | 4- (2-chlorobenzyl) -5,5-dimethyl-2-morpholinyl1-methyl -2-ethoxybenzamide. A target compound was prepared as described in Example 14 (1) using 2-amine of tyl-4- (2-chlorobenzyl) -5,5-dimethylmor folin instead of 2-amio-methyl-4- (2-chloro benzyl) -6-methyl-propanol. T. pl, 18 184 With (from ethyl alcohol). Example 16. Obtaining 4-oh HO-N- (4-benzyl-hexahydro-1,4-oxa zepin-2-sh1) methyl 7-5-chloro 2-ethoxybenzamide. The target compound was prepared according to Example 14 (1), using 2-aminome of 4-benzylhexahydro, 4-oxazepi instead of 2-amino-ethyl-4- (2-chlorobenzyl) -6-methylmorpholine. The free base thus obtained is treated in accordance with Example 14 (2) and the fumarate of the title compound is obtained, mp 180-183 ° C (from isopropyl alcohol). Example 17. Preparation of 4-amino-5-chloro-2-ethoxy-K- (4 - (4-fluorobenzyl) -2-morpholinyl methyl | benzamide. 1. A mixture of 4-acetamino-5-chloro-2-ethoxybenzoic acid methyl ester (2.7 g) and 2-am1 nomethyl-4- (4-fluoro) benzyl) morpholine (5.6 g) is heated with stirring to 150 ° C for 2 hours. After cooling, the reaction mixture is chromatographed on silica gel (chloroform) and the title compound is obtained from To 151-153 C (from these alcohol 2g. The target compound is obtained, as in part 1 of this example, using 4-amino-5-chloro-2-ethoxybenzoic acid methyl ester instead of 4-acetamino-5-chloro-2-ethoxybenzoic acid methyl ester. Examples 18-155 The various compounds listed in Tables 1-4 were prepared as in Examples 1-7, 1, 4, and 17 using the appropriate starting compounds. Example 156. Preparation of 4-am-but-5-chloro-2-ethoxy -K-4- (4-fluorobenzyl) -2-morpholinyl methyl 1benzamide. 1. A mixture of 4-acetylamino-5-chloro-2-ethoxy-N- (4-fluorobenzyl) -2-morpholinyl methyl} benzamide (2.0 g) and 10% hydrochloric acid (40 ml) is heated under reflux with stirring within 1 h and cool. The reaction mixture is neutralized with an aqueous solution of sodium hydroxide and extracted with chloroform. The organic layer is dried over magnesium sulfate and evaporated. The residue is recrystallized from ethanol to obtain the target compound (1.4 g) with so pl. 151-153C.
[2]
2. The free base is dissolved in ethyl alcohol (25 ml) and 35% ethanolic hydrochloric acid (3 ml) is added. The precipitate is collected and recrystallized from ethyl alcohol. The hydrochloride (0.8 g) of the title compound is obtained with mp 160-163 ° C, 3 O 3. The free base (1.0 g) is dissolved in hot ethyl alcohol (15 ml) and citric acid monohydrate (0.53 g is added) ). The mixture is heated until a clear solution is obtained, which is concentrated to 3 ml and cooled. The precipitate is collected and recrystallized from ethyl alcohol and citrate (1.2 g) of the title compound is obtained with a volume of 143-145 ° C. 4. The free base (1.0 g) is dissolved in a hot 10% citric acid solution. acid (40 ml) and the resulting solution is cooled. The precipitate is collected and citrate dihydrate (1.1 g) of the target compound is obtained with a volume of 1 10-1 13 ° C. Example 157. Study of the activity of the compounds of examples 1-156 accelerating gastric emptying. Male Wistar rats weighing 130- 150 g are fixed 18 hours prior to the experiment and 1.5 ml of experimental food (phenol red 0.05% in 1.5% solution, methylcellulose in water) is given through a stomach tube. 15 minutes after the introduction of the food, the stomach is removed and the remaining amount of phenol red in the stomach is measured. Test compounds dissolved or suspended in a 0.5% solution of tragacy are orally administered 60 minutes before the introduction of the experimental food. The degree of gastric emptying is calculated according to the amount of phenol red remaining in the stomach, and the activity of the test compounds is expressed as a percentage of the increase in the degree of emptying from the control. In the control group and for each dose of metoclopradine hydrochloride monohydrate, 5 animals and 4 animals are used for each dose of other tested compounds. The results are presented in table. 5. As can be seen. From table. 5, these compounds exhibit a high activity of accelerating gastric emptying at a dose of 2.0 mg / kg or less. Their action is stronger than that of metoclopramidas hydrochloride monohydrate. Example 158. Study of the acute toxicity of compounds. Male ddx mice weighing 1825 g are used in groups of 10 animals each. The inoculated compounds, dissolved or suspended in a 0.5% plant, are administered orally to the animals in the prescribed dose. Mortality is observed for 7 days after administration. The results are presented in Table 6. Example 159. A study of the effect of compounds on the central nervous system (CNS effect). Male ddx mice weighing 18–25 g are used in groups of three animals each. Comprehensive observation of the behavior and physiological state is carried out within 2 hours after oral treatment with a dose of 100 mg / kg of the tested compound dissolved or suspended in 0.5% tragacanth solution. The effect of test compounds on the CNS is expressed by the following indicators in accordance with the total sum of the effects of individually analyzed effects, such as catelepsy, the omission of the upper eyelid, increased movement and ToDo: -: no effect +: small effect; ++: moderate action; pronounced action. As can be seen from Table 6, both the effects of the CNS effect and the sharpness of the compounds were weaker than those of metoclopramide hydrochloride monohydrate. These data suggest that the proposed compounds have a good time line between the dose for gastric emptying and the dose that has a detrimental effect on the central nervous system. As can be seen from the experimental data presented, the compounds of their pharmaceutically acceptable salts exhibit high activity to enhance the motility of the stomach and intestines with low toxicity and therefore are useful as a means of enhancing gastrointestinal motor function. They can be used to prevent and treat disorders associated with impaired gastrointestinal motility in mammals, including humans, such as dyspepsia, esophageal reflux, gastric congestion, anorexia, nausea, vomiting and abdominal discomfort, which are observed during acute and chronic gastritis, gastric and duodenal ulcers, gastric neurosis, gastroptosis, etc. They can also be used to prevent and treat disorders and blockage of the esophagus and bile duct, to prevent and treat nausea and vomiting associated with the use of vomiting-causing chemotherapeutic agents for cancer treatment, such as cis-platinum. The compounds and their pharmaceutically acceptable acid addition salts can be administered orally, parenterally or intrarectally. The therapeutic dose may vary depending on the type of compound, the route of administration, the severity of the disease, the age of the patient, etc., but is usually in the range of 0.001 to 20 mg per kg of body weight per day, preferably 0.004 to 5 mg per kg of body weight per day. for a man. The dose can be divided and administered two or three times a day. Formula of the invention. A method for producing substituted benzamide derivatives of the formula Y CONH-Xf. (") Where R is ethoxycarbonyl, heteroarylmethyl, where heteroaryl is furyl, thienyl, pyridyl or 1,2-benzisoxazolyl, cinnamyl or a group of the formula -T- (Y) pR, in which T is a simple bond or C -C j -alkylene, Y is oxygen, sulfur or carbonyl, Rg is phenyl, possibly substituted by chlorine, bromine, fluorine, methyl, trifluoromethyl, methoxy, nitro, cyano or amino groups Sing, or R (, - pentafluorophenyl, 2-nitro-4-chlorophenyl, 2,4,6-trimethylphenyl, naphthyl or diphenylmethyl, p O or 1 provided that if T is a simple bond, then p is zero, K is fluorine, chlorine, hydroxy, C — C, p-alkoxy, cyclopentyloxy, C, —C-alkenyloxy, 2-propenyloxy, (2-methoxyethoxy) methoxy , 2-oxopropoxy, a free amino group monosubstituted with C-C alkyl, benzyl or cyclopropyl amino group, a propoxy group in which the carbon atom in any position other than the I position is substituted by one hydroxy or amino group, or C, -Cj alkoxy, substituted by chlorine , cyano, ethoxycarbonyl, phthalimido, Cj-C-cycloalkyl, phenyl, benzoyl, p-fluorophenoxy, or p-fluorobenzoyl; R is hydrogen; R is hydrogen, chlorine, amino, methylamino, di (C, -C 2 -alkyl) amino, acetylamino or nitro; R is hydrogen, chlorine, bromine, nitro, sulfamoyl, or methylsulfamoyl, or any two adjacent groups R, R2, Rj, and R4 are combined to form methylenedioxy, and the remaining two groups are each hydrogen; Rj. - hydrogen or methyl; X - C, -C-alkylene; each type is equal to one or c and k in J O mgd Il 2Q in gd 30, and but 35 n to two, provided that at least one of the groups R, R, or R is not hydrogen, and their pharmaceutically acceptable slot addition salts, which are based on the fact that the compound of the formula for formula coR e R, RJ, RJ and R have the indicated meanings, and its reactive derivative with the compound of the formula H, N-Xr ° 1 e R, RJ-, X, type have the indicated meanings, provided the desired product in free-form or in the form of a pharmaceutically acceptable acid addition salt. The priority for the prize is 30.04.86 when item 1. 12/31/86 when item 2.
15
C1 „1 #., SOKSN, -y °
1597101
Table 1
Difunarath
20
Sc. 21 (1) CH, 5 (HCl.V) -4HjO 21 (2) 22CH, .C1 Difumarate.
,
Fumarat
C1 C,
r.F
s.Etipavy alcohol 99-103
F f
26 : CHi-O- "
Me
Sesquifumarate 192-194 Ie
ai "-Q
Sesquifumarate CFi / 2H, 0
SI,
29
Sesquifumarat150-167
SI,
OyMapaT-l / 4HjO154-156
thirty
ome
CHi-O- ° "
1 / 511.0
CM
ai.-t
185-187
103-151
89-91
79-82
96-99
61-64
162-165 Isopropyl alcohol J72-185 144-147 Isopropyl 175-181 Ethyl alcohol
7
33- "
34 SI,
CH, H,
35
36 (CHi) iCjHj
37CH (CHj), 538CH (CH,)
39CH (
CH,
AO
CH,
R
41
CH
42
43CH, 44
P
45CH, V
46. N
Sn.
47
CH,
48
18
1597101
Continued table. one
G ---: - TOKSAPDD / ZN About 68-172 Ethyl alcohol
97-99 Methyl alcohol
2-Isopropyl 80-85 Isopropyl
 alcohol
1/4 isopropyl alcohol 175-176-1 / 5H, 0
Fumarat-i / 2H20171-175 Ethyl alcohol
OKcanaT- / it jC 228-231
l / ah-jo
184-186
Fumarat-Ethyl 155-158 Ethyl Alcohol Ethyl Ethyl Sulfur
3/4 ethyl128-131 Ethyl alcohol
alcohol
Semifumarate. 166-168 Ethyl alcohol 1 / 4H, 0 diethyl ether
Semifumarate-I / 4158-160 Ethyl alcohol
EtOH-1 / 3420Diethyl ether
1/5 mjo
146-147 Isopropyl alcohol - diisopropyl ether
Sesquifumarat. H 88 88-91
Oxalate-5/4 124-135 Ethyl alcohol EtOH-3 / lO (CO
167-170 Isopropyl alcohol.
127-129 Ethyl alcohol
Semifumarate. 1/2 N, 0
1597101
nineteen
LlZIZ ZIIIIZI
49CH, CH (CHj) dCjHj Oxalate lCH,) zO-Q-f. 1/4 isopropic 148-150 alcohol
. (CH) ZO-OG
1/2 isopropyl 127-131. alcohol 1/5 N, 0
-Cl
. (CH,)} 053lCHi) Cesquifumarate. (CH. Oxalate 1/4 HjO 164-166 (CH,) Cesquifumarate 120-122
(aijljO- Q-cN
1/4
56 571 ™ OzO1 / 5 ethyl alcohol 58 (CH,) ,, Oxalate. 3/2 EtOH 1/2 HjO 59 (C) 60CH. Ethyl alcohol 1/5 61 (CH,) Fumarate 62CH CH CH-Ph Cesquifumarate 3/4 HjO i
20
Continued tab
::: o ::::: i
. ,,
113-115 Ethyl alcohol
123-126
170-172 Isopropyl alcohol Isopropyl alcohol 158-161 Ethyl alcohol diethyl ether Ethyl alcohol Ethyl alcohol diethyl ether 149-153 Ethyl alcohol 212-216 127-130 Isopropyl alcohol 102-106 Ethyl alcohol 148-155 124-147 Ethyl diethyl ether
Clv srv COMHCH, 0
H, -XXo.t%
1/4 HjO
HCl-3/4 CHjCjH / F
Difumarat
CH, .r
CH, Fumarat
66, (1) sn,
Hel-l / 2HjO181-1-83
eleven
66 (2)
67CH, -O
68 (1) -CHi-Oci
68 (2) - 2HC1
g f
sn.
1/4 EtOH
F g
Pfl
70sn.nc
71СН-Ь
3/10 HjO
SNG-O
Oksalat-1/2 EtOH-HjO
SI.O-SM
73
CH, -R-C1
1/10 CHC1 op l / 5HjO,
75 (CH,),
Oxalate-7/4 HjO
76 (CH,) C4Hj. Oksalat3 / 2
T. table 2
R
 Ethyl alcohol 200-203 Ethyl alcohol
175-178
Iopropyl ether
183-184
144-147 Ethyl alcohol
155-158
150-151
216-223
162-164
146-149
154-158 Isopropyl alcohol
194-198 Ethyl alcohol
170-172 Methyl alcohol
202-205 Chloroform
138-141- Ethyl alcohol 168-174- iirzizi 77СН (СН 3)
"(- Y-O-S
78
Sn.-O 79N
Fumarat
CH;
Fumarate 1/2 ieo80-0) propyl alcohol Dimaleat-1/2 HjO. 80 (2)
sn.
81 82 (CH,) goO-C1 Oxalate 1/2 E10I 83 (CH, 84 (SNg) 3/4 oxalate-2H40
85
(.five.
1/4 HjO
С1.SOЯNSN, °
,
860 (Cn) jCH3
CHjCjHj.
87OCHCCHj)
ciij (
880 (CHj) jCHj
ClIjCjU
CH, Oh
89
SI. -O C1
90
131-141
Isopropyl alcohol
182-185
150-152
175-176 Isopropyl alcohol 1/4
163-165 Isopropyl alcohol
Table 3
192-195, ethyl alcohol
184-186, ethyl alcohol
188-190, ethyl alcohol
178-184 ethyl alcohol
196-201, ethyl alcohol Oxalate. 3/4 H O135-137 Ethyl alcohol Continued table. 2 iz :: ii; diethyl ether 133-135 Ethyl alcohol 186-188 Ethyl alcohol 149-151 135-138 Methyl alcohol
OCH, - {3
112 OC1I, Cjllj
1 13
ztnlovp) alcohol
103-108, ethyl alcohol - diethyl ether
SI, -O-1
117OCH CH-CCCHj)
CH.
CI
oh (n)
,
OCHjCECH
0 (CH,) 50-O-F
121
.122OCHjCOCjII,
123 oicHzbeo-Q-f
1-27
MI.,
128
lir
129
NHCI1,
c: i
Na; i,),
130
vy spirit
170-172, ethyl
DifuMarath alcohol
138-141, ethyl
alcohol - isopropyl alcohol
189-192, ethyl alcohol
143-147, ethyl alcohol
145-147, ethyl alcohol
207-210, ethyl alcohol
Sesquifumarate "202-205, ethyl
alcohol
188-194, methyl
alcohol
147-149, acetoluene
158-162, ethyl
-alcohol
132-134, isopropyl alcohol
29
NHCOCH 3H
OSI,
134
NH,
135
thirty
1597101
Long 2 e H1 1e table.
108-113, neopropyl alcohol
119-122, isopropyl alcohol - hexane
1 (1)
6
eight
18 (2)
63 (1)
66 (1)
67
68 (1)
70
74
80 (1)
81
88
89
90
91
93
94
95
97
101
104
105
0/10
2/10
0/10
6/10
0/10
0/10
5/10
0/10
0/10
0/10
4/10
0/10
2/10
0/10
0/10
4/10
0/10
3/10
0/10
0/10
2/10
3/10
0/10
116-1 / 0
119-5 / 10
Metaclopramide ++ H-5/0
In all examples, the oral dose was 1000 mg / kg, in the case of methaclopramide 200 mg / kg.

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1597101A3|1990-09-30|Method of producing derivatives of substituted benzamide or their pharmaceutically acceptable acid-additive salts

---

US4065584A|1977-12-27|Sulphur containing arylamine derivatives

---

EP0089167B1|1986-10-15|Dihydropyridine anti-ischaemic and antihypertensive agents, processes for their production, and pharmaceutical compositions containing them

---

SU1417796A3|1988-08-15|Versions of method of producing pyridine-2-ethers or pyridine-2-thioethers or acid-additive salts thereof,or pyridine-n-oxides

---

US4808624A|1989-02-28|Pharmacologically active substituted benzamides

---

US4820715A|1989-04-11|Anti-emetic quinuclidinyl benzamides

---

EP0193148A2|1986-09-03|8-Chlorodibenz[b,f][1,4]oxazepine-10|-carboxylic acid, 2-|hydrazides

---

SK45096A3|1997-01-08|Alkoxy alkyl carbamates from imidazo |pyridines, preparation method thereof, pharmaceutical composition containing them and their use

---

SK287606B6|2011-03-04|Pyridine-1-oxide derivative, its use and process for its transformation into pharmaceutically effective compounds

---

US4091100A|1978-05-23|Sulfide compounds

---

US4056632A|1977-11-01|2-Hydroxymethyl-2&#39;-aminomethyl-diphenylsulfides and method of use

---

EP1043308A1|2000-10-11|Phenylaminoalkylcarboxylic acid derivatives and medicinal compositions containing the same

---

JP4113602B2|2008-07-09|Pyrrolidine derivatives and anti-ulcer agents, antibacterial agents

---

US4301159A|1981-11-17|N-|-2-alkoxy-benzamide derivatives

---

CS256400B2|1988-04-15|Method of new pyridylmethylsulphinylthieno|imidazole derivatives production

---

US4271188A|1981-06-02|Compounds having hypolipidaemic activity

---

JPH11100366A|1999-04-13|New n-substituted cyclic amine derivative and its production

---

WO1993023049A1|1993-11-25|3-|-5-hydroxymethylaniline derivatives as anticancer agents

---

US5258406A|1993-11-02|Sulfonimidamides

---

GB1561521A|1980-02-20|3,4 - dihydro - 3 - oxo - 4-carbamoyl - 2h - thieno | - 1 - 2-thiazine 1,1 - dioxide derivatives

---

US4734411A|1988-03-29|Pyrrolizidine compounds, salts thereof, process for the preparation of same and pharmaceutical agents comprising same

---

EP0072013B1|1986-04-16|Pyrrole compounds as anti-inflammatory and analgesic agents

---

US3954981A|1976-05-04|Triazolocycloalkylhydrothiadiazine derivatives

---

US4132796A|1979-01-02|Antipsychotic 3-trifluoromethylsulfinyl analogs of cyproheptadine

---

DD256325A5|1988-05-04|PROCESS FOR PREPARING SUBSTITUTED BENZAMID DERIVATIVES

同族专利:

---

公开号 | 公开日

---

DE3781195D1|1992-09-24|

---

KR870010030A|1987-11-30|

---

CA1291135C|1991-10-22|

---

FI871828A0|1987-04-27|

---

CZ284687B6|1999-02-17|

---

HUT45514A|1988-07-28|

---

FI87776C|1993-02-25|

---

SK289787A3|1998-06-03|

---

EP0243959B1|1992-08-19|

---

GR3005934T3|1993-06-07|

---

HU198193B|1989-08-28|

---

US4870074A|1989-09-26|

---

DK175281B1|2004-08-09|

---

EP0243959A1|1987-11-04|

---

AU592177B2|1990-01-04|

---

ES2043617T3|1994-01-01|

---

DK218787A|1987-10-31|

---

HK18194A|1994-03-11|

---

FI87776B|1992-11-13|

---

NZ220120A|1989-06-28|

---

CZ289787A3|1998-11-11|

---

PH24049A|1990-03-05|

---

AR242953A1|1993-06-30|

---

DK218787D0|1987-04-29|

---

AU7227587A|1987-11-05|

---

FI871828A|1987-10-31|

---

SK279058B6|1998-06-03|

---

DE3781195T2|1993-02-18|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

CH451142A|1965-01-19|1968-05-15|Sandoz Ag|Process for the preparation of new basic substituted benzoic acid amides|

---

US4029786A|1972-08-11|1977-06-14|Imperial Chemical Industries Limited|Morpholine derivatives for treating depression|

---

US4323503A|1976-08-04|1982-04-06|Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France|Substituted 2,3-alkylene di benzamides and derivatives|

---

US4210754A|1977-02-01|1980-07-01|Hoffmann-La Roche Inc.|Morpholino containing benzamides|

---

US4692445A|1983-04-29|1987-09-08|Rorer Pharmaceutical Corporation|Bicyclic benzenoid aminoalkylene ethers and thioethers, pharmaceutical compositions and use|

---

FR2575158B1|1984-12-20|1987-10-02|Pf Medicament|ARYLALCOYLOXYMETHYL-2 MORPHOLINS, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS|

---

JPH0390274A|1989-08-28|1991-04-16|Furukawa Alum Co Ltd|Vapor brazing method for al or al alloy|

---

SE467473B|1990-03-15|1992-07-20|Goeran Anderberg|AXELTAETNING|FR2640139A1|1988-12-14|1990-06-15|Delagrange Laboratoires|APPLICATION OF BENZAMIDES SUBSTITUTED AS GASTROMOTORS|

---

US5395832A|1991-02-15|1995-03-07|Hokuriku Seiyaku Co., Ltd.|Benzamide derivatives|

---

TW243449B|1991-02-15|1995-03-21|Hokuriku Pharmaceutical|

---

WO1995026953A1|1994-03-30|1995-10-12|Yoshitomi Pharmaceutical Industries, Ltd.|Benzoic acid compound and use thereof as medicine|

---

US5864039A|1994-03-30|1999-01-26|Yoshitomi Pharmaceutical Industries, Ltd.|Benzoic acid compounds and use thereof as medicaments|

---

NZ309065A|1995-05-23|1999-06-29|Janssen Pharmaceutica Nv|benzamide derivatives having gastrointestinal motility stimulating properties|

---

CN1678594A|2000-09-29|2005-10-05|葛兰素集团有限公司|Morpholin-acetamide derivatives for the treatment of inflammatory diseases|

---

AT286897T|2000-11-28|2005-01-15|Smithkline Beecham Plc|MORPHOLIN DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS|

---

JP4829417B2|2001-03-26|2011-12-07|明夫 乾|Insulin resistance improving drug|

---

CA2463168A1|2001-10-08|2003-04-17|Sun Pharmaceutical Industries Limited|An antispasmodic agent spaced drug delivery system|

---

GB0207449D0|2002-03-28|2002-05-08|Glaxo Group Ltd|Novel compounds|

---

GB0207447D0|2002-03-28|2002-05-08|Glaxo Group Ltd|Novel compounds|

---

GB0208158D0|2002-03-28|2002-05-22|Glaxo Group Ltd|Novel compounds|

---

HU0201980A3|2002-06-13|2008-06-30|Richter Gedeon Nyrt|Process for preparing a benzamide derivative and intermediates thereof|

---

CN1913876B|2003-12-09|2013-06-26|大日本住友制药株式会社|Drug-containing grains and solid preparation containing the grains|

---

US8524736B2|2004-01-07|2013-09-03|Armetheon, Inc.|Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders|

---

US8138204B2|2004-01-07|2012-03-20|Aryx Therapeutics, Inc.|Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders|

---

DK2194053T3|2004-01-07|2013-07-01|Armetheon Inc|Methoxypiperidine derivatives for use in the treatment of gastrointestinal and central nervous system disorders.|

---

PT1801108E|2004-09-08|2012-12-03|Mitsubishi Tanabe Pharma Corp|Morpholine compounds for the treatment of inflammations|

---

WO2007002157A2|2005-06-23|2007-01-04|Array Biopharma Inc.|Process for preparing benzimidazole compounds|

---

US7326787B2|2005-08-31|2008-02-05|Aryx Therapeutics, Inc.|Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders|

---

JP2009520820A|2005-12-20|2009-05-28|メルクエンドカムパニーインコーポレーテッド|Niacin receptor agonist, composition containing said compound and method of treatment|

---

KR100750593B1|2006-03-16|2007-08-20|동우신테크 주식회사|Process for preparing substituted benzamide derivatives|

---

US20080085915A1|2006-06-23|2008-04-10|Cyrus Becker|Compounds and methods for the treatment of gastrointestinal and central nervous system disorders|

---

KR20100012031A|2007-04-19|2010-02-04|콘서트 파마슈티컬즈, 인크.|Deuterated morpholinyl compounds|

---

CN101402633A|2007-09-11|2009-04-08|上海恒瑞医药有限公司|Benzamide derivatives, preparation method and medical uses thereof|

---

CN102006861B|2008-02-13|2012-11-21|大日本住友制药株式会社|Orally disintegrating tablets|

---

TWI423967B|2008-02-21|2014-01-21|Dainippon Sumitomo Pharma Co|Amide derivative and pharmaceutical composition comprising the same|

---

CN101565381B|2009-06-01|2013-07-24|重庆英斯凯化工有限公司|Method for preparing 2-alkoxy-4-amino-5-chlorobenzoic acid|

---

WO2011019043A1|2009-08-11|2011-02-17|大日本住友製薬株式会社|Tablet that disintegrates rapidly in the mouth and that contains two or more types of particles|

---

WO2011107903A1|2010-03-04|2011-09-09|Ranbaxy Laboratories Limited|Highly pure mosapride citrate dihydrate and processes for its preparation|

---

CA2827030C|2011-02-25|2019-01-08|Yuhan Corporation|Diaminopyrimidine derivatives and processes for the preparation thereof|

---

KR101657616B1|2013-05-24|2016-09-19|주식회사유한양행|Bicyclic derivatives containing pyrimidine ring and processes for the preparation thereof|

---

TW201808286A|2016-05-11|2018-03-16|滬亞生物國際有限公司|Combination therapies of HDAC inhibitors and PD-L1 inhibitors|

---

TW201740943A|2016-05-11|2017-12-01|滬亞生物國際有限公司|Combination therapies of HDAC inhibitors and PD-1 inhibitors|

---

CN111349052B|2020-04-07|2021-02-12|福建海西新药创制有限公司|Synthesis method of mosapride citrate|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

JP10155286|1986-04-30|

---

JP31509086|1986-12-31|

---